Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
BIOLASE, INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).
- Exchange
- nasdaq
- Notice
- extension granted
- Deficiency
- stockholders equity
- Rules
- 5550(b)
Exact text from the filing
February 13, 2024, the Company received notice from the Staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff had determined to grant the Company an extension of time to regain compliance with Listing Rule 5550(b) (the “Rule”). The Rule requires a minimum $2,500,000 stockholders’ equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations. As previously announced, on November 14, 2023, the Company received a deficiency letter from the Nasdaq notifying it that, based on its stockholders’
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BIOLASE, INC entered into Securities Purchase Agreement with certain institutional investors (effective 2024-02-13).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional investors
- Effective
- 2024-02-13
Exact text from the filing
the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) dated February 13, 2024, with certain institutional investors signatory thereto, pursuant to which the Company agreed to issue and sell to such investors, certain of the Securities sold in the Offering.
View on SEC.gov